Lexeo stock drops 24% amid Friedreich Ataxia study results

seekingalpha07-16

Shares of Lexeo Therapeutics (NASDAQ:LXEO) tumbled 24% after the company reported interim Phase 1/2 clinical data for its drug LX2006 for the treatment of Friedreich Ataxia, or FA, cardiomyopathy. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2451662094?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/867183762/image_867183762.jpg","is_english":true,"pubTime":"2024-07-16 00:03","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2451662094","market":"us","top_or_hot":-1,"title":"Lexeo stock drops 24% amid Friedreich Ataxia study results","media":"seekingalpha","content":"<div>\n<p>Shares of Lexeo Therapeutics (NASDAQ:LXEO) tumbled 24% after the company reported interim Phase 1/2 clinical data for its drug LX2006 for the treatment of Friedreich Ataxia, or FA, cardiomyopathy. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4124338-lexeo-stock-drops-amid-friedreich-ataxia-study-results\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexeo stock drops 24% amid Friedreich Ataxia study results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexeo stock drops 24% amid Friedreich Ataxia study results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-16 00:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4124338-lexeo-stock-drops-amid-friedreich-ataxia-study-results><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Lexeo Therapeutics (NASDAQ:LXEO) tumbled 24% after the company reported interim Phase 1/2 clinical data for its drug LX2006 for the treatment of Friedreich Ataxia, or FA, cardiomyopathy. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4124338-lexeo-stock-drops-amid-friedreich-ataxia-study-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://seekingalpha.com/news/4124338-lexeo-stock-drops-amid-friedreich-ataxia-study-results","article_id":"2451662094","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/867183762/image_867183762.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2451662094","pubTimestamp":1721059432,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Lexeo Therapeutics  tumbled 24% after the company reported interim Phase 1/2 clinical data for its drug LX2006 for the treatment of Friedreich Ataxia, or FA, cardiomyopathy. Lexeo said that based on the drug’s observed safety profile and clinical benefits, it plans to explore expedited development for the product, including possible accelerated regulatory approval. The company noted that there are currently no approved treatments for FA cardiomyopathy, according to a statement.  The company plans to share additional details of the results at a scientific conference in the fall. Last year, Biogen’s  Skyclarys became the first FDA-approved prescription drug to treat FA, a progressive neuromuscular disease that can also cause cardiomyopathy and diabetes. Other companies working on treatments for FA include Larimar Therapeutics , PTC Therapeutics , Astellas  , Voyager Therapeutics , Design Therapeutics , Prime Medicine  and Solid Biosciences .","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BIIB":"渤健公司","BK4505":"高瓴资本持仓","LXEO":"Lexeo Therapeutics","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LRMR":"Larimar Therapeutics, Inc.","VYGR":"Voyager Therapeutics Inc","BK4539":"次新股","DSGN":"Design Therapeutics, Inc.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4532":"文艺复兴科技持仓","ALPMY":"Astellas Pharma, Inc.","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","ALPMF":"Astellas Pharma, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","FA":"First Advantage Corp.","PRME":"Prime Medicine, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4130":"人力资源与就业服务","BK4007":"制药","SLDB":"Solid Biosciences","PTCT":"PTC Therapeutics Inc.","BK4535":"淡马锡持仓"},"translate_title":"Friedreich共济失调研究结果导致Lexeo股价下跌24%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALPMY":1,"VYGR":1,"SLDB":1,"PTCT":1,"PRME":1,"LXEO":1,"LRMR":1,"DSGN":1,"ALPMF":1,"BIIB":1,"FA":0.69},"content_text":"Shares of Lexeo Therapeutics (NASDAQ:LXEO) tumbled 24% after the company reported interim Phase 1/2 clinical data for its drug LX2006 for the treatment of Friedreich Ataxia, or FA, cardiomyopathy. Lexeo said that based on the drug’s observed safety profile and clinical benefits, it plans to explore expedited development for the product, including possible accelerated regulatory approval. The company noted that there are currently no approved treatments for FA cardiomyopathy, according to a statement.  The company plans to share additional details of the results at a scientific conference in the fall. Last year, Biogen’s (BIIB) Skyclarys became the first FDA-approved prescription drug to treat FA, a progressive neuromuscular disease that can also cause cardiomyopathy and diabetes. Other companies working on treatments for FA include Larimar Therapeutics (LRMR), PTC Therapeutics (PTCT), Astellas (OTCPK:ALPMF) (OTCPK:ALPMY), Voyager Therapeutics (VYGR), Design Therapeutics (DSGN), Prime Medicine (PRME) and Solid Biosciences (SLDB).","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451662094"}